A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Elisabeth I. Heath, Keith Bible, Robert E. Martell, Daniel C. Adelman, Patricia M. LoRusso

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences